Adagene Inc. has entered into a licensing agreement with Third Arc Bio, enabling the latter to utilize Adagene’s innovative SAFEbody technology for the development of two masked CD3 T cell engagers targeting unique tumor-associated antigens. The agreement grants Third Arc Bio worldwide rights to research, develop, and commercialize these candidate molecules, with Adagene receiving an upfront payment of $5 million and potential milestone payments totaling up to $840 million, alongside royalties on sales. Additionally, Adagene retains a no-cost option for development and commercialization in Greater China, Singapore, and South Korea.
Peter Luo, Ph.D., CEO of Adagene, emphasized the advantages of SAFEbody technology, which activates antibodies specifically within the tumor microenvironment, thus enhancing therapeutic efficacy while minimizing off-target toxicity. This strategic collaboration is expected to bolster Third Arc Bio’s portfolio of novel T cell engagers, as noted by CEO Peter Lebowitz, M.D., Ph.D., who highlighted the potential of Adagene’s technology to expand their innovative pipeline.
Adagene, a clinical-stage biotechnology firm, is committed to revolutionizing antibody-based cancer immunotherapies through its advanced platforms and strategic partnerships. The SAFEbody technology, designed to mitigate safety challenges in antibody therapeutics, is a key component of Adagene’s differentiated pipeline, which includes its lead clinical program, ADG126 (muzastotug), currently in advanced clinical trials. This collaboration not only enhances Third Arc Bio’s capabilities but also emphasizes the growing trend of precision medicine in oncology.
Open the full market picture for your next decision →
